JSCO Podcast January - February 2018

Friday, March 23, 2018

In this podcast, Dr. Henry highlights research articles on analgesic management in radiation oncology for painful bone metastases, hospitalizations for fracture in patients with metastatic disease, measurement of physical activity and sedentary behavior in breast cancer survivors, and patient navigators’ personal experiences with cancer and their impact on treatment. He also discusses a New Therapies review article on hallmark tumor metabolism becoming a validated therapeutic target, as well as The JCSO Interview, in which Kenneth Anderson, MD, talks about new myeloma drugs and their associated improved response rates and extended survival.

How to Listen

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.



More Episodes from Blood & Cancer

View All Episodes

Close